Dupilumab (Dupixent®) for severe asthma. HTA ID: 21063

Assessment Status Rapid review complete
HTA ID 21063
Drug Dupilumab
Brand Dupixent®
Indication For adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance.
Assessment Process
Rapid review commissioned 13/12/2021
Rapid review completed 08/02/2022
Rapid review outcome A full HTA is not recommended. The NCPE recommends that dupilumab (Dupixent®) not be considered for reimbursement at the submitted price*

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.